TheraRadar
← Back
Data updated: Jun 28, 2026

DBL PHARMS

Generics
Pharmaceuticals

DBL PHARMS is a generic drug manufacturer with 1 FDA-approved products.

2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

DBL PHARMS's Key Drugs

DBL PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

DBL PHARMS's Recent FDA Approvals

New NDA/BLA approvals for DBL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

DBL PHARMS's Therapeutic Areas

Disease areas where DBL PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

DBL PHARMS Pipeline Snapshot

Active clinical trials for DBL PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling